A Phase 2 interventional study of Anakinra 100 mg and Triamcinolone Acetonide 40 mg in Acute Gouty Arthritis, sponsored by Swedish Orphan Biovitrum. Completed at 37 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-15.
Sponsored by Swedish Orphan Biovitrum · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 164 studies in Gout with a site in United States — 12 open to participants now, 16 under way, 3 of them phase 3. Gout · United States.
Among the 164 studies in Gout with a site in United States, this one is the 51st largest by enrollment of the 149 interventional ones that give a count, is one of 2 that started in 2016, is one of 45 in phase 2, and was the 87th registered.
347 studies on the registry are indexed under Gout; 50 are open to participants now.
Browse Gout studies →12 of the 164 studies in Gout with a site in United States are open now. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18–80
Crystalys Therapeutics · Sites in United States
Ages 18–75
Amgen · Sites in United States, Puerto Rico
Ages 18+
ANI Pharmaceuticals · Sites in United States
Ages 18–90
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
164 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 50 · Phase 3 31 · Phase 4 22
First in 1998; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 165 is above the median of 83 across 288 interventional studies indexed under Gout.
Median enrollment 74 across the 149 interventional studies, 188 across the 15 observational. Of the 138 that completed or were terminated, 69 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
119 of 164 have an industry lead sponsor. The 10 most frequent:
Swedish Orphan Biovitrum is the lead sponsor of 82 studies on the registry; 6 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Swedish Orphan Biovitrum has 9 studies filed under Gout — fewer than ten, so there is no comparison to draw.
7 of the studies in Gout with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05658575Phase 3Olatec Therapeutics, Inc.Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | 2026-12-31 |
| NCT07089875Phase 3Crystalys TherapeuticsA Study of Dotinurad Versus Allopurinol in Participants With Gout | 2027-11-29 |
| NCT07116746Arthrosi TherapeuticsEvaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients | 2026-11 |
| NCT06534554University of Alabama at BirminghamImproving Gout Care After an ED Visit | 2027-01-01 |
| NCT07535034Crystalys TherapeuticsA Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants | 2027-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 164 studies in Gout with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate how anakinra relieves pain for patients with acute gout that cannot take non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine. The patients will be divided in different treatment groups to compare anakinra to the available drug triamcinolone.
Patients will be randomized to treatment at their first gout flare in the study. The first treatment period will be followed by an extension period during which the patients will receive the same treatment for any subsequent flares within 52 weeks of randomization of last patient in the study. The extension period for the individual patient in the study will be maximum two years (104 weeks). Each new flare treated will initiate a new series of study visits and assessments according to specified schedule of events. Only if a patient experience a new flare after Day 15 of the latest flare they can start a new treatment period. The comparison of primary interest is between anakinra (100 mg and 200 mg combined) and 40 mg triamcinolone, and as a secondary objective the 2 different doses of anakinra will be evaluated as well as assessment for subsequent flares.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion criteria for treatment of subsequent flare(s)
Exclusion Criteria:
Exclusion criteria for treatment of subsequent flare(s):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 subcutaneous injection of Anakinra 100 mg once daily for 5 days, 1 subcutaneous injection of Placebo to Anakinra 100 mg once daily for 5 days and 1 single intramuscular injection of Placebo to Triamcinolone Acetonide 40 mg
Drug: Anakinra 100 mg · Drug: Placebo to Anakinra 100 mg · Drug: Placebo to Triamcinolone Acetonide 40 mg
2 subcutaneous injections of Anakinra 100 mg (2 syringes) once daily for 5 days and 1 single intramuscular injection of Placebo to Triamcinolone Acetonide 40 mg
Drug: Anakinra 100 mg · Drug: Placebo to Triamcinolone Acetonide 40 mg
2 subcutaneous injections of Placebo to Anakinra 100 mg once daily for 5 days and 1 single intramuscular injection of Triamcinolone Acetonide 40 mg
Drug: Triamcinolone Acetonide 40 mg · Drug: Placebo to Anakinra 100 mg
100 mg/0.67 mL solution in single-use prefilled syringes for subcutaneous injection
Also known as: Kineret
1 mL intramuscular injection of a 40 mg/mL injectable suspension
Also known as: Kenalog, Triamcinolone
sterile solution for injection (0.67 mL) in a single-use prefilled syringe identical to the anakinra syringe
Also known as: Placebo Kineret
1 mL intramuscular injectable suspension with identical appearance as the Triamcinolone Acetonide suspension
Also known as: Placebo Kenalog
Change in Patient-assessed Pain Intensity in the Index Joint From Baseline to 24-72 Hours for the First Gout Flare Treated in the Study as Measured by VAS
Patients will score their pain intensity in the joint most affected at baseline (index joint) on a 0-100 mm visual analogue scale (VAS), ranging from no pain (0) to unbearable pain (100). Average of the assessments performed at 24, 48 and 72 hours.
Time frame: At baseline (pre-dose) and at 24, 48 and 72 hours for the first gout flare treated in the study
Change in Patient-assessed Pain Intensity in the Index Joint From Baseline at Time Points From 6 Hours to 8 Days for the First Gout Flare Treated in the Study as Measured by 5-point Likert Scale
Patients will score their pain intensity in the joint most affected at baseline (index joint) on a 5-point Likert scale (0-4 point scale: "none", "mild", "moderate", "severe", "extreme") at time points baseline (pre-dose) and at 6, 12, 18, 24, 36, 48 and 72 hours and Day 5, 6, 7 and 8.
Time frame: At baseline (pre-dose) and at 6, 12, 18, 24, 36, 48 and 72 hours and Day 5, 6, 7 and 8 for the first gout flare treated in the study
Median Time to Onset of Effect
Onset of effect defined as 20% change from baseline pain intensity in the index joint on a visual analogue scale (VAS)
Time frame: From baseline (predose) up to Day15 of the first flare treated in the study
Median Time to Response
Response defined as 50% change from baseline pain intensity on a visual analogue scale (VAS)
Time frame: From baseline (predose) up to Day15 of the first flare treated in the study
Median Time to Resolution of Pain
Resolution of pain defined as \<10 mm on VAS, a continuous 0 to 100 mm visual analogue scale, ranging from no pain (0) to unbearable pain (100), in the index joint
Time frame: From baseline (predose) up to Day15 of the first flare
Median Time to First Intake of Rescue Medication From First Investigational Drug Administration
Time to first intake of rescue medication for acute gout, measured in hours from first investigational drug administration
Time frame: From Day 1 to Day 15 for the first flare treated
Physician's Assessment of Global Response to Treatment
5-point Likert scale (0- to 4-point scale: "none", "mild", "moderate", "severe, "extreme") where higher score mean worse outcome
Time frame: At 72 hours, Day 8 and Day 15 for the first flare treated in the study
Physician's Assessment of Clinical Signs in Index Joint: Tenderness
4-point Likert scale (0=no pain, 1= mild/patient states there is pain when touched, 2= moderate/patient states there is pain and Winces, 3=severe/patient states there is pain, winces and withdraws
Time frame: at 72 hours, Day 8 and Day 15 for the first flare treated in the study
Physician's Assessment of Clinical Signs in Index Joint: Swelling
4-point Likert scale (0=no swelling, 1= mild swelling, 2=moderate swelling, 3=severe swelling or bulging beyond joint margins)
Time frame: at 72 hours, Day 8 and Day 15 for the first flare treated in the study
Physician's Assessment of Clinical Signs in Index Joint: Erythema
Physicians assessment of clinical signs with 2 outcomes: Absent=no erythema, present=erythema
Time frame: at 72 hours, Day 8 and Day 15 for the first flare treated in the study
Patient´s Assessment of Global Response to Treatment (5-point Likert Scale)
5-point Likert scale (0- to 4-point scale: 0=excellent, 1=very good, 2=good, 3=fair, 4=poor response to treatment) where lower rate indicates better response to treatment
Time frame: at 72 hours, Day 8 and Day 15 for the first flare treated in the study
Change From Baseline in the Inflammatory Biomarker C Reactive Protein
This endpoint represents the change from baseline, mg/dL, of the inflammatory biomarker C reactive protein
Time frame: baseline (predose) and at 72 hours, Day 8 and Day 15 for the first flare treated in the study
Change From Baseline in the Inflammatory Biomarker Serum Amyloid A
This endpoint represents the change from baseline, mg/L, of the inflammatory biomarker Serum amyloid A
Time frame: baseline (predose) and at 72 hours, Day 8 and Day 15 for the first flare treated in the study
The Percent of Patients With at Least One Adverse Event
All adverse events to be recorded Day 1 - Day 28 for each flare. Serious adverse events (SAE) will be collected from informed consent until week 12 for each flare. Any SAE with suspected causal relationship should be reported irrespective of the time of occurrence.
Time frame: Through study completion, at 12 weeks after last flare treated during the extension period
The Percent of Patients With at Least One Serious Adverse Event, Including Death
Serious Adverse Events (SAE) will be collected from informed consent until week 12 for each flare. Any SAE with suspected causal relationship should be reported irrespective of the time of occurrence.
Time frame: Through study completion, at 12 weeks after last flare treated during the extension period
Serum Concentration of Endogenous Interleukin-1 Receptor Antagonist /Anakinra
This endpoint represents the level of of endogenous interleukin-1 receptor antagonist /anakinra
Time frame: Baseline (predose) and at 72 hours, Day 8, Day 15, Day 28 and Week 12 for the first flare and subsequent flares treated during the extension period
Proportion of Patients With Anti-drug Antibodies (ADA) Against Anakinra
Confirmed ADA positive samples will be analysed for the presence of neutralizing antibodies
Time frame: Baseline (predose) and at 72 hours, Day 8, Day 15, Day 28 and Week 12 for the first flare and subsequent flares treated treated during the extension period
Proportion of Patients With Neutralizing Antibodies
Confirmed ADA positive samples will be analysed for the presence of neutralizing antibodies
Time frame: Baseline (predose) and at 72 hours, Day 8, Day 15, Day 28 and Week 12 for the first flare and subsequent flares treated during the extension period
Change From Baseline in Short Form (36) Health Survey, Acute Version 2 (SF-36®) Physical Functioning Domain Score
SF-36® measures the impact of disease on overall quality of life. It consists of 8 individual domains. Score range from 0 to 100, where 0 represents the worst possible health and 100 is perfect health.
Time frame: at baseline, Day 8 and Day 15 for the first flare treated in the study
Change From Baseline in Health Related Quality of Life EuroQol 5 Dimensions 5 Levels (EQ-5D-5L)
Exploratory objective. The EQ-5D-5L, a self-report questionnaire, is a descriptive system of Health related quality of life (HRQL) states consisting of 5 dimensions (Mobility, Self-care, Usual activities, Pain/Discomfort, Anxiety/Depression), each of which can have 5 responses. The responses record 5 levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.
Time frame: at baseline, Day 8 and Day 15 for the first flare treated in the study
Percent Impairment While Working During Last Week Due to Gout During the First Flare and Subsequent Flares
The WPAI yeilds four types of scores of which Work productivity loss is one. SHP is derived from WPAI as follows: The WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity as follows: Questions: Q1 = currently employed Q2 = hours missed due to specified problem Q3 = hours missed other reasons Q4 = hours actually worked Q5 = degree problem affected productivity while working Q6 = degree problem affected regular activities Scores: Multiply scores by 100 to express in percentages. Percent impairment while working due to problem: Q5/10 The answer on Q5 is given on a scale from 0 (PROBLEM had no effect on work) to 10 (PROBLEM completely prevented me from working). Thus the analysis values from which mean and SD have been calculated and reported are the outcomes from Q5 (ranging from 0 to 10) multiplied with 100 and divided by 10.
Time frame: Recorded up to Day 15 for the first flare and subsequent flares treated during the extension period
Health Care Resource Utilization Due to a Gouty Arthritis Flare
Exploratory objective: number of days with hospitalization and un-scheduled outpatient visits
Time frame: Recorded up to Day 15 for the first flare and subsequent flares treated during the extension period
| Milestone | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| Started | 55 | 56 | 54 |
| Intention to treat populatio | 55 | 56 | 54 |
| Safety population | 54 | 55 | 52 |
| Completed | 35 | 40 | 36 |
| Not completed | 20 | 16 | 18 |
Patients will score their pain intensity in the joint most affected at baseline (index joint) on a 0-100 mm visual analogue scale (VAS), ranging from no pain (0) to unbearable pain (100). Average of the assessments performed at 24, 48 and 72 hours.
| Units on a scale | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| 24 hours | -26.1 (-32.5 to -19.6) | -32.5 (-38.8 to -26.1) | -31.1 (-37.6 to -24.6) |
| 48 hours | -43.4 (-50.8 to -36.0) | -42.9 (-50.0 to -35.9) | -43.6 (-51.0 to -36.3) |
| 72 hours | -45.2 (-52.7 to -37.7) | -51.6 (-58.9 to -44.3) | -49.1 (-56.5 to -41.6) |
Patients will score their pain intensity in the joint most affected at baseline (index joint) on a 5-point Likert scale (0-4 point scale: "none", "mild", "moderate", "severe", "extreme") at time points baseline (pre-dose) and at 6, 12, 18, 24, 36, 48 and 72 hours and Day 5, 6, 7 and 8.
| Score on a scale | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| 6 hours | -0.6 ± 0.7 | -0.8 ± 0.9 | -0.4 ± 0.8 |
| 12 hours | -0.9 ± 0.6 | -1.1 ± 1.2 | -0.5 ± 0.7 |
| 18 hours | -0.8 ± 0.8 | -1.2 ± 1.0 | -0.8 ± 0.9 |
| 24 hours | -1.0 ± 0.8 | -0.9 ± 1.0 | -1.1 ± 0.9 |
| 36 hours | -1.3 ± 0.8 | -1.3 ± 1.0 | -1.1 ± 0.7 |
| 48 hours | -1.5 ± 1.0 | -1.4 ± 1.0 | -1.5 ± 1.0 |
| 72 hours | -1.6 ± 1.1 | -1.6 ± 1.0 | -1.7 ± 0.9 |
| Day 5 | -1.8 ± 1.1 | -1.8 ± 1.1 | -1.8 ± 1.1 |
| Day 6 | -1.9 ± 1.1 | -2.2 ± 1.1 | -1.9 ± 1.0 |
| Day 7 | -2.4 ± 0.8 | -2.2 ± 1.1 | -1.9 ± 1.0 |
| Day 8 | -1.9 ± 0.9 | -2.1 ± 1.1 | -2.1 ± 1.0 |
Onset of effect defined as 20% change from baseline pain intensity in the index joint on a visual analogue scale (VAS)
| Hours | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| Median Time to Onset of Effect | 22.3 (13.9 to 24.6) | 11.8 (7.7 to 24.0) | 19.8 (12.1 to 30.0) |
Response defined as 50% change from baseline pain intensity on a visual analogue scale (VAS)
| Hours | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| Median Time to Response | 47.6 (40.3 to 67.7) | 43.0 (18.6 to 70.4) | 46.9 (24.1 to 67.4) |
Resolution of pain defined as \<10 mm on VAS, a continuous 0 to 100 mm visual analogue scale, ranging from no pain (0) to unbearable pain (100), in the index joint
| Hours | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| Median Time to Resolution of Pain | 167.5 (120.1 to 264.2) | 131.8 (70.9 to NA) | 119.8 (69.0 to 144.2) |
Time to first intake of rescue medication for acute gout, measured in hours from first investigational drug administration
| Hours | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| Median Time to First Intake of Rescue Medication From First Investigational Drug Administration | NA (126.5 to NA) | NA (114.4 to NA) | NA (220.7 to NA) |
5-point Likert scale (0- to 4-point scale: "none", "mild", "moderate", "severe, "extreme") where higher score mean worse outcome
| Score on a scale | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| 72 hours | 1.54 (1.23 to 1.85) | 1.25 (0.94 to 1.55) | 1.25 (0.94 to 1.56) |
| Day 8 | 1.26 (0.93 to 1.59) | 0.90 (0.59 to 1.20) | 0.81 (0.48 to 1.14) |
| Day 15 | 1.04 (0.69 to 1.39) | 0.80 (0.47 to 1.13) | 0.78 (0.46 to 1.13) |
4-point Likert scale (0=no pain, 1= mild/patient states there is pain when touched, 2= moderate/patient states there is pain and Winces, 3=severe/patient states there is pain, winces and withdraws
| Participants | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| 72 hours : None | 8 | 18 | 16 |
| 72 hours : Mild | 22 | 28 | 25 |
| 72 hours : Moderate | 17 | 4 | 9 |
| 72 hours : Severe | 4 | 3 | 1 |
| 72 hours : Missing | 4 | 3 | 3 |
| Day 8 : None | 19 | 28 | 30 |
| Day 8 : Mild | 25 | 19 | 17 |
| Day 8 : Moderate | 4 | 2 | 1 |
| Day 8 : Severe | 1 | 4 | 1 |
| Day 8 : Missing | 6 | 3 | 5 |
| Day 15 : None | 37 | 38 | 32 |
| Day 15 : Mild | 10 | 9 | 12 |
| Day 15 : Moderate | 1 | 5 | 5 |
| Day 15 : Severe | 1 | 1 | 0 |
| Day 15 : Missing | 6 | 3 | 5 |
4-point Likert scale (0=no swelling, 1= mild swelling, 2=moderate swelling, 3=severe swelling or bulging beyond joint margins)
| Participants | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| Baseline : None | 0 | 0 | 0 |
| Baseline : Mild | 9 | 14 | 7 |
| Baseline : Moderate | 23 | 27 | 28 |
| Baseline : Severe | 23 | 15 | 18 |
| Baseline : Missing | 0 | 0 | 1 |
| 72 hours : None | 14 | 27 | 17 |
| 72 hours : Mild | 22 | 18 | 26 |
| 72 hours : Moderate | 10 | 7 | 7 |
| 72 hours : Severe | 5 | 1 | 1 |
| 72 hours : Missing | 4 | 3 | 3 |
| Day 8 : None | 25 | 37 | 38 |
| Day 8 : Mild | 16 | 13 | 9 |
| Day 8 : Moderate | 7 | 2 | 2 |
| Day 8 : Severe | 1 | 1 | 0 |
| Day 8 : Missing | 6 | 3 | 5 |
| Day 15 : None | 37 | 44 | 34 |
| Day 15 : Mild | 9 | 6 | 14 |
| Day 15 : Moderate | 2 | 3 | 1 |
| Day 15 : Severe | 1 | 0 | 0 |
| Day 15 : Missing | 6 | 3 | 5 |
Physicians assessment of clinical signs with 2 outcomes: Absent=no erythema, present=erythema
| Participants | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| Baseline : Absent | 3 | 8 | 8 |
| Baseline : Present | 51 | 48 | 45 |
| Baseline : Missing | 1 | 0 | 1 |
| 72 hours : Absent | 29 | 39 | 37 |
| 72 hours : Present | 22 | 14 | 14 |
| 72 hours : Missing | 4 | 3 | 3 |
| Day 8 : Absent | 43 | 43 | 40 |
| Day 8 : Present | 6 | 9 | 9 |
| Day 8 : Missing | 6 | 4 | 5 |
| Day 15 : Absent | 47 | 47 | 40 |
| Day 15 : Present | 2 | 5 | 9 |
| Day 15 : Missing | 6 | 4 | 5 |
5-point Likert scale (0- to 4-point scale: 0=excellent, 1=very good, 2=good, 3=fair, 4=poor response to treatment) where lower rate indicates better response to treatment
| Participants | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| 72 hours : Excellent | 11 | 10 | 18 |
| 72 hours : Very good | 13 | 19 | 9 |
| 72 hours : Good | 7 | 14 | 15 |
| 72 hours : Fair | 7 | 4 | 3 |
| 72 hours : Poor | 4 | 1 | 1 |
| 72 hours : Missing | 13 | 8 | 8 |
| Day 8 : Excellent | 9 | 16 | 19 |
| Day 8 : Very good | 16 | 21 | 13 |
| Day 8 : Good | 8 | 6 | 7 |
| Day 8 : Fair | 5 | 6 | 2 |
| Day 8 : Poor | 5 | 0 | 1 |
| Day 8 : Missing | 12 | 7 | 12 |
| Day 15 : Excellent | 14 | 19 | 21 |
| Day 15 : Very good | 9 | 13 | 11 |
| Day 15 : Good | 10 | 8 | 10 |
| Day 15 : Fair | 6 | 5 | 3 |
| Day 15 : Poor | 3 | 0 | 1 |
| Day 15 : Missing | 13 | 11 | 8 |
This endpoint represents the change from baseline, mg/dL, of the inflammatory biomarker C reactive protein
| mg/dL | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| 72 hours | -0.362 ± 3.435 | -1.435 ± 2.057 | -1.362 ± 1.682 |
| Day 8 | -0.321 ± 2.153 | -1.334 ± 2.702 | 1.406 ± 1.961 |
| Day 15 | -1.102 ± 1.690 | -0.724 ± 2.525 | -0.607 ± 2.646 |
This endpoint represents the change from baseline, mg/L, of the inflammatory biomarker Serum amyloid A
| mg/L | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| 72 hours | 8.950 ± 246.317 | -45.160 ± 126.986 | -34.510 ± 58.518 |
| Day 8 | -6.363 ± 117.794 | -46.561 ± 144.630 | -35.887 ± 64.144 |
| Day 15 | -50.524 ± 105.170 | -25.328 ± 144.039 | 14.370 ± 146.627 |
All adverse events to be recorded Day 1 - Day 28 for each flare. Serious adverse events (SAE) will be collected from informed consent until week 12 for each flare. Any SAE with suspected causal relationship should be reported irrespective of the time of occurrence.
| Percent | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| The Percent of Patients With at Least One Adverse Event | 40.7 | 38.2 | 55.8 |
Serious Adverse Events (SAE) will be collected from informed consent until week 12 for each flare. Any SAE with suspected causal relationship should be reported irrespective of the time of occurrence.
| Percent | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| The Percent of Patients With at Least One Serious Adverse Event, Including Death | 0 | 7.3 | 0 |
This endpoint represents the level of of endogenous interleukin-1 receptor antagonist /anakinra
| ng/mL | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| First flare : Baseline | 2.032 ± 2.493 | 4.883 ± 24.378 | 1.950 ± 2.755 |
| First flare : 72 hours | 1.974 ± 1.793 | 267.744 ± 246.086 | 628.053 ± 540.488 |
| First flare : Day 8 | 1.692 ± 1.343 | 6.750 ± 10.439 | 34.777 ± 87.812 |
| First flare : Day 15 | 1.533 ± 0.226 | 1.588 ± 0.443 | 1.574 ± 0.356 |
| First flare : Day 28 | 1.635 ± 0.615 | 1.659 ± 1.057 | 1.779 ± 0.895 |
| First flare : Week 12 | 1.500 ± 0.000 | 1.625 ± 0.478 | 1.719 ± 0.681 |
| Second flare : Baseline | 1.748 ± 1.024 | 1.718 ± 0.732 | 1.500 ± 0.00 |
| Second flare : 72 hours | 1.628 ± 0.526 | 254.930 ± 249.962 | 719.667 ± 840.530 |
| Second flare : Day 8 | 3.141 ± 6.270 | 7.048 ± 20.338 | 48.785 ± 114.114 |
| Second flare : Day 15 | 1.845 ± 1291 | 1.595 ± 0.457 | 1.500 ± 0.00 |
| Second flare : Day 28 | 1.975 ± 1.714 | 1.692 ± 0.882 | 1.500 ± 0.00 |
| Second flare : Week 12 | 2.920 ± 4.490 | 1.681 ± 0.725 | 1.692 ± 0.636 |
| Third flare : Baseline | 2.05 ± 1.24 | 1.50 ± 0.00 | 1.50 ± 0.00 |
| Third flare : 72 hours | 1.85 ± 0.78 | 196.67 ± 192.56 | 431.63 ± 298.51 |
| Third flare : Day 8 | 1.50 ± 0.00 | 5.56 ± 12.97 | 10.70 ± 15.42 |
| Third flare : Day 15 | 1.50 ± 0.00 | 1.63 ± 0.44 | 1.50 ± 0.00 |
| Third flare : Day 28 | 1.85 ± 0.78 | 1.50 ± 0.00 | 2.47 ± 2.38 |
| Third flare : Week 12 | 2.85 ± 1.91 | 1.50 ± 0.00 | 1.50 ± 0.00 |
| Fourth flare : Baseline | 1.50 ± 0.00 | 1.50 ± 0.00 | 1.50 ± 0.00 |
| Fourth flare : 72 hours | 1.50 ± 0.00 | 184.40 ± 198.19 | 916.62 ± 1549.55 |
| Fourth flare : Day 8 | 1.50 ± 0.00 | 1.89 ± 1.02 | 20.62 ± 34.10 |
| Fourth flare : Day 15 | 1.50 ± 0.00 | 1.50 ± 0.00 | 1.50 ± 0.00 |
| Fourth flare : Day 28 | 1.50 ± 0.00 | 1.50 ± 0.00 | 1.50 ± 0.00 |
| Fourth flare : Week 12 | 1.50 ± 0.00 | 2.66 ± 2.60 | 1.50 ± 0.00 |
| Fifth flare : Baseline | 1.50 ± 0.00 | 1.50 ± 0.00 | 1.50 ± 0.00 |
| Fifthe flare : 72 hours | 1.50 ± 0.00 | 129.20 ± 200.26 | 292.35 ± 308.56 |
| Fifthe flare : Day 8 | 1.50 ± 0.00 | 1.50 ± 0.00 | 6.39 ± 9.49 |
| Fifthe flare : Day 15 | 1.50 ± 0.00 | 1.50 ± 0.00 | 1.50 ± 0.00 |
| Fifthe flare : Day 28 | 1.50 ± 0.00 | 3.31 ± 2.55 | 1.50 ± 0.00 |
| Fifth flare : Week 12 | 1.50 ± 0.00 | — | 1.50 ± 0.00 |
Confirmed ADA positive samples will be analysed for the presence of neutralizing antibodies
| participants | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| First flare : Baseline | 2 | 5 | 2 |
| First flare : Day 8 | 1 | 4 | 3 |
| First flare : Day 15 | 0 | 5 | 4 |
| First flare : Day 28 | 0 | 4 | 2 |
| First flare : Week 12 | 0 | 4 | 0 |
| Second flare : Baseline | 0 | 0 | 2 |
| Second flare : Day 8 | 0 | 1 | 2 |
| Second flare : Day 15 | 0 | 1 | 0 |
| Second flare : Day 28 | 0 | 1 | 1 |
| Second flare : Week 12 | 0 | 0 | 1 |
| Third flare : Baseline | 0 | 0 | 2 |
| Third flare : Day 8 | 0 | 1 | 4 |
| Third flare : Day 15 | 0 | 1 | 4 |
| Third flare : Day 28 | 0 | 1 | 0 |
| Third flare : Week 12 | 0 | 0 | 0 |
| Fourth flare : Baseline | 0 | 0 | 2 |
| Fourth flare : Day 8 | 0 | 1 | 3 |
| Fourth flare : Day 15 | 0 | 1 | 4 |
| Fourth flare : Day 28 | 0 | 1 | 1 |
| Fourth flare : Week 12 | 0 | 1 | 0 |
| Fifth flare : Baseline | 0 | 0 | 1 |
| Fifth flare : Day 8 | 0 | 1 | 2 |
| Fifth flare : Day 15 | 0 | 2 | 2 |
| Fifth flare : Day 28 | 0 | 1 | 2 |
| Fifth flare : Week 12 | 0 | 0 | 0 |
Confirmed ADA positive samples will be analysed for the presence of neutralizing antibodies
| participants | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| First flare : Baseline | 0 | 0 | 0 |
| First flare : Day 8 | 0 | 0 | 0 |
| First flare : Day 15 | 0 | 0 | 0 |
| First flare : Day 28 | 0 | 0 | 0 |
| First flare : Week 12 | 0 | 0 | 0 |
| Second flare : Study baseline | 0 | 0 | 0 |
| Second flare : Flare baseline | 0 | 0 | 0 |
| Second flare : Day 8 | 0 | 0 | 0 |
| Second flare : Day 15 | 0 | 0 | 0 |
| Second flare : Day 28 | 0 | 0 | 0 |
| Second flare : Week 12 | 0 | 0 | 0 |
| Third flare : Study baseline | 0 | 0 | 0 |
| Third flare : Flare baseline | 0 | 0 | 0 |
| Third flare : Day 8 | 0 | 0 | 0 |
| Third flare : Day 15 | 0 | 0 | 0 |
| Third flare : Day 28 | 0 | 0 | 0 |
| Third flare : Week 12 | 0 | 0 | 0 |
| Fourth flare : Study baseline | 0 | 0 | 0 |
| Fourth flare : Flare baseline | 0 | 0 | 0 |
| Fourth flare : Day 8 | 0 | 1 | 0 |
| Fourth flare : Day 15 | 0 | 0 | 1 |
| Fourth flare : Day 28 | 0 | 0 | 0 |
| Fourth flare : Week 12 | 0 | 0 | 0 |
| Fifth flare : Study baseline | 0 | 0 | 0 |
| Fifth flare : Flare baseline | 0 | 0 | 0 |
| Fifth flare : Day 8 | 0 | 0 | 0 |
| Fifth flare : Day 15 | 0 | 0 | 0 |
| Fifth flare : Day 28 | 0 | 0 | 0 |
| Fifth flare : Week 12 | 0 | 0 | 0 |
SF-36® measures the impact of disease on overall quality of life. It consists of 8 individual domains. Score range from 0 to 100, where 0 represents the worst possible health and 100 is perfect health.
| units on a scale | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| Day 8 | 8.0 ± 9.8 | 10.5 ± 10.0 | 10.4 ± 8.3 |
| Day 15 | 11.8 ± 8.2 | 12.2 ± 11.9 | 9.4 ± 8.7 |
Exploratory objective. The EQ-5D-5L, a self-report questionnaire, is a descriptive system of Health related quality of life (HRQL) states consisting of 5 dimensions (Mobility, Self-care, Usual activities, Pain/Discomfort, Anxiety/Depression), each of which can have 5 responses. The responses record 5 levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.
| Participants | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| Mobility scores : Day 8 — Improvement 4 step | 2 | 1 | 0 |
| Mobility scores : Day 8 — Improvement 3 step | 5 | 6 | 5 |
| Mobility scores : Day 8 — Improvement 2 step | 12 | 9 | 11 |
| Mobility scores : Day 8 — Improvement 1 step | 5 | 18 | 12 |
| Mobility scores : Day 8 — No change | 14 | 7 | 9 |
| Mobility scores : Day 8 — Deterioration 1 steps | 3 | 3 | 2 |
| Mobility scores : Day 8 — Deterioration 2 steps | 0 | 3 | 0 |
| Mobility scores : Day 8 — Deterioration 3 steps | 0 | 0 | 0 |
| Mobility scores : Day 8 — Detorioration 4 steps | 0 | 0 | 0 |
| Mobility scores : Day 8 — Missing | 14 | 9 | 15 |
| Mobility scores : Day 15 — Improvement 4 step | 2 | 1 | 0 |
| Mobility scores : Day 15 — Improvement 3 step | 7 | 7 | 2 |
| Mobility scores : Day 15 — Improvement 2 step | 11 | 10 | 15 |
| Mobility scores : Day 15 — Improvement 1 step | 8 | 16 | 10 |
| Mobility scores : Day 15 — No change | 9 | 5 | 14 |
| Mobility scores : Day 15 — Deterioration 1 steps | 1 | 4 | 2 |
| Mobility scores : Day 15 — Deterioration 2 steps | 0 | 1 | 0 |
| Mobility scores : Day 15 — Deterioration 3 steps | 0 | 0 | 0 |
| Mobility scores : Day 15 — Detorioration 4 steps | 0 | 0 | 0 |
| Mobility scores : Day 15 — Missing | 17 | 12 | 11 |
| Self-care scores : Day 8 — Improvement 4 step | 2 | 1 | 0 |
| Self-care scores : Day 8 — Improvement 3 step | 3 | 3 | 3 |
| Self-care scores : Day 8 — Improvement 2 step | 4 | 3 | 7 |
| Self-care scores : Day 8 — Improvement 1 step | 7 | 11 | 6 |
| Self-care scores : Day 8 — No change | 23 | 27 | 22 |
| Self-care scores : Day 8 — Deterioration 1 steps | 1 | 1 | 1 |
| Self-care scores : Day 8 — Deterioration 2 steps | 1 | 1 | 0 |
| Self-care scores : Day 8 — Deterioration 3 steps | 0 | 0 | 0 |
| Self-care scores : Day 8 — Detorioration 4 steps | 0 | 0 | 0 |
| Self-care scores : Day 8 — Missing | 14 | 9 | 15 |
| Selfcare scores : Day 15 — Improvement 4 step | 2 | 1 | 0 |
| Selfcare scores : Day 15 — Improvement 3 step | 2 | 3 | 1 |
| Selfcare scores : Day 15 — Improvement 2 step | 5 | 5 | 7 |
| Selfcare scores : Day 15 — Improvement 1 step | 8 | 10 | 10 |
| Selfcare scores : Day 15 — No change | 20 | 21 | 25 |
| Selfcare scores : Day 15 — Deterioration 1 steps | 1 | 3 | 0 |
| Selfcare scores : Day 15 — Deterioration 2 steps | 0 | 1 | 0 |
| Selfcare scores : Day 15 — Deterioration 3 steps | 0 | 0 | 0 |
| Selfcare scores : Day 15 — Detorioration 4 steps | 0 | 0 | 0 |
| Selfcare scores : Day 15 — Missing | 17 | 12 | 11 |
| Usual activities scores : Day 8 — Improvement 4 step | 3 | 0 | 0 |
| Usual activities scores : Day 8 — Improvement 3 step | 3 | 6 | 2 |
| Usual activities scores : Day 8 — Improvement 2 step | 15 | 11 | 13 |
| Usual activities scores : Day 8 — Improvement 1 step | 10 | 14 | 9 |
| Usual activities scores : Day 8 — No change | 6 | 12 | 14 |
| Usual activities scores : Day 8 — Deterioration 1 steps | 4 | 2 | 1 |
| Usual activities scores : Day 8 — Deterioration 2 steps | 0 | 2 | 0 |
| Usual activities scores : Day 8 — Deterioration 3 steps | 0 | 0 | 0 |
| Usual activities scores : Day 8 — Detorioration 4 steps | 0 | 0 | 0 |
| Usual activities scores : Day 8 — Missing | 14 | 9 | 15 |
| Usual activities scores : Day 15 — Improvement 4 step | 2 | 1 | 0 |
| Usual activities scores : Day 15 — Improvement 3 step | 8 | 7 | 0 |
| Usual activities scores : Day 15 — Improvement 2 step | 10 | 11 | 13 |
| Usual activities scores : Day 15 — Improvement 1 step | 10 | 12 | 13 |
| Usual activities scores : Day 15 — No change | 6 | 9 | 14 |
| Usual activities scores : Day 15 — Deterioration 1 steps | 2 | 3 | 2 |
| Usual activities scores : Day 15 — Deterioration 2 steps | 0 | 1 | 1 |
| Usual activities scores : Day 15 — Deterioration 3 steps | 0 | 0 | 0 |
| Usual activities scores : Day 15 — Detorioration 4 steps | 0 | 0 | 0 |
| Usual activities scores : Day 15 — Missing | 17 | 12 | 11 |
| Pain/discomfort scores : Day 8 — Improvement 4 step | 3 | 3 | 0 |
| Pain/discomfort scores : Day 8 — Improvement 3 step | 5 | 11 | 11 |
| Pain/discomfort scores : Day 8 — Improvement 2 step | 16 | 12 | 15 |
| Pain/discomfort scores : Day 8 — Improvement 1 step | 12 | 15 | 9 |
| Pain/discomfort scores : Day 8 — No change | 4 | 4 | 4 |
| Pain/discomfort scores : Day 8 — Deterioration 1 steps | 0 | 1 | 0 |
| Pain/discomfort scores : Day 8 — Deterioration 2 steps | 1 | 1 | 0 |
| Pain/discomfort scores : Day 8 — Deterioration 3 steps | 0 | 0 | 0 |
| Pain/discomfort scores : Day 8 — Detorioration 4 steps | 0 | 0 | 0 |
| Pain/discomfort scores : Day 8 — Missing | 14 | 9 | 15 |
| Pain/discomfort scores : Day 15 — Improvement 4 step | 3 | 3 | 1 |
| Pain/discomfort scores : Day 15 — Improvement 3 step | 9 | 11 | 10 |
| Pain/discomfort scores : Day 15 — Improvement 2 step | 17 | 13 | 14 |
| Pain/discomfort scores : Day 15 — Improvement 1 step | 5 | 11 | 10 |
| Pain/discomfort scores : Day 15 — No change | 3 | 2 | 8 |
| Pain/discomfort scores : Day 15 — Deterioration 1 steps | 1 | 3 | 0 |
| Pain/discomfort scores : Day 15 — Deterioration 2 steps | 0 | 1 | 0 |
| Pain/discomfort scores : Day 15 — Deterioration 3 steps | 0 | 0 | 0 |
| Pain/discomfort scores : Day 15 — Detorioration 4 steps | 0 | 0 | 0 |
| Pain/discomfort scores : Day 15 — Missing | 17 | 12 | 11 |
| Anxiety/depression scores : Day 8 — Improvement 4 step | 1 | 0 | 0 |
| Anxiety/depression scores : Day 8 — Improvement 3 step | 2 | 2 | 0 |
| Anxiety/depression scores : Day 8 — Improvement 2 step | 3 | 0 | 3 |
| Anxiety/depression scores : Day 8 — Improvement 1 step | 5 | 9 | 9 |
| Anxiety/depression scores : Day 8 — No change | 26 | 33 | 25 |
| Anxiety/depression scores : Day 8 — Deterioration 1 steps | 4 | 3 | 2 |
| Anxiety/depression scores : Day 8 — Deterioration 2 steps | 0 | 0 | 0 |
| Anxiety/depression scores : Day 8 — Deterioration 3 steps | 0 | 0 | 0 |
| Anxiety/depression scores : Day 8 — Detorioration 4 steps | 0 | 0 | 0 |
| Anxiety/depression scores : Day 8 — Missing | 14 | 9 | 15 |
| Anxiety/depression scores : Day 15 — Improvement 4 step | 1 | 0 | 0 |
| Anxiety/depression scores : Day 15 — Improvement 3 step | 1 | 2 | 0 |
| Anxiety/depression scores : Day 15 — Improvement 2 step | 4 | 1 | 3 |
| Anxiety/depression scores : Day 15 — Improvement 1 step | 7 | 6 | 10 |
| Anxiety/depression scores : Day 15 — No change | 23 | 33 | 26 |
| Anxiety/depression scores : Day 15 — Deterioration 1 steps | 0 | 2 | 4 |
| Anxiety/depression scores : Day 15 — Deterioration 2 steps | 2 | 0 | 0 |
| Anxiety/depression scores : Day 15 — Deterioration 3 steps | 0 | 0 | 0 |
| Anxiety/depression scores : Day 15 — Detorioration 4 steps | 0 | 0 | 0 |
| Anxiety/depression scores : Day 15 — Missing | 17 | 12 | 11 |
The WPAI yeilds four types of scores of which Work productivity loss is one. SHP is derived from WPAI as follows: The WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity as follows: Questions: Q1 = currently employed Q2 = hours missed due to specified problem Q3 = hours missed other reasons Q4 = hours actually worked Q5 = degree problem affected productivity while working Q6 = degree problem affected regular activities Scores: Multiply scores by 100 to express in percentages. Percent impairment while working due to problem: Q5/10 The answer on Q5 is given on a scale from 0 (PROBLEM had no effect on work) to 10 (PROBLEM completely prevented me from working). Thus the analysis values from which mean and SD have been calculated and reported are the outcomes from Q5 (ranging from 0 to 10) multiplied with 100 and divided by 10.
| percent | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| First flare : Day 8 | 36.1 ± 34.3 | 32.6 ± 29.1 | 20.5 ± 25.0 |
| First flare : Day 15 | 23.3 ± 24.8 | 12.6 ± 20.7 | 21.6 ± 22.3 |
| Second flare : Day 8 | 42.9 ± 27.5 | 24.0 ± 26.3 | 24.0 ± 27.2 |
| Second flare : Day 15 | 16.0 ± 25.1 | 20.0 ± 17.6 | 13.8 ± 16.9 |
| Third flare : Day 8 | 10.0 | 5.0 ± 7.1 | 10.0 ± 10.0 |
| Third flare : Day 15 | 10.0 | 20.0 ± 24.5 | 23.3 ± 32.1 |
| Fourth flare : Day 8 | 30.0 | — | 20.0 ± 34.6 |
| Fourth flare : Day 15 | — | — | 5.0 ± 7.1 |
| Fifth flare : Day 8 | 60.0 | — | 26.7 ± 25.2 |
| Fifth flare : Day 15 | 20.0 | 40.0 | 13.3 ± 11.5 |
Exploratory objective: number of days with hospitalization and un-scheduled outpatient visits
| days | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| Hospitalization : First flare : Day 1-7 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Hospitalization : First flare : Day 8-15 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Hospitalization : First flare : Day 1-15 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Hospitalization : Second flare : Day 1-7 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Hospitalization : Second flare : Day 8-15 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Hospitalization : Second flare : Day 1-15 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Hospitalization : Third flare : Day 1-7 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Hospitalization : Third flare : Day 8-15 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Hospitalization : Third flare : Day 1-15 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Hospitalization : Fourth flare : Day 1-7 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Hospitalization : Fourth flare : Day 8-15 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Hospitalization : Fourth flare : Day 1-15 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Hospitalization : Fifth flare : Day 1-7 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Hospitalization : Fifth flare : Day 8-15 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Hospitalization : Fifth flare : Day 1-15 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Unscheduled outpatient visits:First flare: Day 1-7 | 0.1 ± 0.5 | 0 ± 0 | 0.1 ± 0.6 |
| Unscheduled outpatient visits:First flare:Day 8-15 | 0.3 ± 1.4 | 0.1 ± 0.6 | 0 ± 0 |
| Unscheduled outpatient visits:First flare:Day 1-15 | 0.4 ± 1.4 | 0.1 ± 0.6 | 0.1 ± 0.6 |
| Unscheduled outpatient visits:Second flare:Day 1-7 | 0.2 ± 0.8 | 0 ± 0 | 0 ± 0 |
| Unscheduled outpatient visit:Second flare:Day 8-15 | 0.2 ± 0.6 | 0 ± 0 | 0 ± 0 |
| Unscheduled outpatient visit:Second flare:Day 1-15 | 0.5 ± 1.5 | 0 ± 0 | 0 ± 0 |
| Unscheduled outpatient visits:Third flare:Day 1-7 | 0.4 ± 0.9 | 0 ± 0 | 0 ± 0 |
| Unscheduled outpatient visits:Third flare:Day 8-15 | 0.4 ± 0.9 | 0 ± 0 | 0 ± 0 |
| Unscheduled outpatient visits:Third flare:Day 1-15 | 0.8 ± 1.8 | 0 ± 0 | 0 ± 0 |
| Unscheduled outpatient visitstFourth flare:Day 1-7 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Unscheduled outpatient visitsFourth flare:Day 8-15 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Unscheduled outpatient visitsFourth flare:Day 1-15 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Unscheduled outpatient visit:Fifth flare : Day 1-7 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Unscheduled outpatient visitFifth flare : Day 8-15 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Unscheduled outpatient visit Fifth flare:Day 1-15 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
Collected over The period for recording all adverse events, including SAEs begins upon receiving the first dose of Investigational medicinal product (IMP) and ends with a follow-up telephone call 5 weeks after the first dose of IMP. SAEs will also be collected from signing of the Informed consent form (ICF) until the Week 12 visit. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Triamcinolone 40 mg | 0/54 (0%) | 0/54 (0%) | 22/54 (40.7%) |
| Anakinra 100 mg | 0/55 (0%) | 4/55 (7.3%) | 19/55 (34.5%) |
| Anakinra 200 mg | 0/52 (0%) | 1/52 (1.9%) | 29/52 (55.8%) |
| Event | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| Coronary artery diseaseCardiac disorders | 0/54 | 1/55 | 1/52 |
| AnaemiaBlood and lymphatic system disorders | 0/54 | 1/55 | 0/52 |
| SeizureNervous system disorders | 0/54 | 1/55 | 0/52 |
| Gastric ulcerGastrointestinal disorders | 0/54 | 1/55 | 0/52 |
| Sickel cell anaemiaCongenital, familial and genetic disorders | 0/54 | 1/55 | 0/52 |
| Event | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg |
|---|---|---|---|
| InfluenzaInfections and infestations | 0/54 | 3/55 | 5/52 |
| Blood triglycerides increasedInvestigations | 1/54 | 0/55 | 5/52 |
| NeutropeniaBlood and lymphatic system disorders | 0/54 | 1/55 | 3/52 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 0/54 | 3/55 | 2/52 |
| HeadacheNervous system disorders | 2/54 | 0/55 | 2/52 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/54 | 2/55 | 2/52 |
| MicroalbuminuriaRenal and urinary disorders | 0/54 | 0/55 | 2/52 |
| Oedema peripheralGeneral disorders | 0/54 | 1/55 | 2/52 |
| Injection site hypersensitivityGeneral disorders | 0/54 | 0/55 | 2/52 |
| Ligament sprainInjury, poisoning and procedural complications | 1/54 | 0/55 | 2/52 |
| Age, Continuous(years) | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg | Total |
|---|---|---|---|---|
| Mean | 56.8 ± 10.3 | 53.7 ± 11.9 | 54.0 ± 13.1 | 54.8 ± 11.8 |
| Sex: Female, Male(Participants) | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg | Total |
|---|---|---|---|---|
| Female | 7 | 8 | 7 | 22 |
| Male | 48 | 48 | 47 | 143 |
| Race/Ethnicity, Customized(Participants) | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg | Total |
|---|---|---|---|---|
| Race — White | 39 | 38 | 42 | 119 |
| Race — Black or African American | 15 | 15 | 12 | 42 |
| Race — Asian | 1 | 3 | 0 | 4 |
| Region of Enrollment(participants) | Triamcinolone 40 mg | Anakinra 100 mg | Anakinra 200 mg | Total |
|---|---|---|---|---|
| United States | 55 | 56 | 54 | 165 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2016 to primary completion in Jun 2018, 18 months.
Results were first posted in Jul 2020, 2 years 1 month after primary completion. A results delay was requested in Jun 2018.
Of 25 industry-sponsored phase 2 interventional studies under Gout, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 19. This study's 18 months is above that.
Counting every sponsor, half of 30 studies reached it within 14 months; a quarter within 7 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interleukin 1 Receptor Antagonist Protein